Efficacy of Novel Syk-Kinase Inhibitors MT-SYK-03 and MT-SYK-322 in Cellular Models of Autoimmunity and Cancer

摘要

Novel rationally-designed Syk-kinase inhibitor MT-SYK-03 demonstrated equal potency with R406 (active metabolite of Fostamatinib, a phase III clinical trial candidate) in cellular models of autoimmunity and cancer with EC50 values in sub-micromolar range, while MT-SYK-322 was less active.